Laguna Hills, California (PRWEB) May 31, 2009
BioMeDevice Ltd. announced today that it is seeking concerned physicians and tension type headache (TTH) /migraine sufferers to actively participate in a broad-based, physician supervised pilot study program to ascertain the efficacy of the FDA approved gumEase® cryoanesthesia dental device in treating migraine and tension type (TTH) headache pain safely, without drugs and their unwelcome side effects.
The gumEase® cryoanesthesia mouthpiece is designed to be used as a safe and efficacious method of delivering anesthesia for dental and oral pain. Inserted in the oral sulci/canal, a regional pain block is achieved by the local application of extreme cold to the superior dental plexus and it's nerves, near freezing the nerve fibers and temporarily blocking the connectivity ability of the nerves to transmit pain impulses to the brain.
Anecdotal data provided by dental patients using the gumEase® device in aftercare treatment, also experimented with the gumEase® as another method to control their headache pain with much success. Preliminary research conducted by BioMeDevice Ltd. suggests that the application of cold to the nerves (in this case via the gumEase®) will provide substantive relief to the migraine/headache sufferer without medication or anesthetic gels.
At the present time, the study is scheduled to commence in early July with anticipated completion by October 1, 2009. All participating physicians will receive copies of preliminary results for their review and copies of the final report as well.
For additional information please contact
Tay Reynolds McClellan
Director, Research and Development